PARP inhibitor has positive outcomes in Phase III trial in selected men with mCRPC

According to a media release issued jointly yesterday by AstraZeneca and Merck, treatment with the PARP inhibitor olaparib (Lynparza) has demonstrated “positive results from the Phase III PROfound trial … in [a subset of] men with metastatic castration-resistant prostate cancer (mCRPC).” … READ MORE …

Phase III trial of olaparib in first-line treatment of mCRPC

Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …

Talazoparib + enzalutamide in treatment of mCRPC

Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Preliminary data from the TRITON 2 trial of rucaparib in mCRPC

A poster presented at the ESMO meeting in Munich has just reported data from an unplanned, preliminary analysis of data from the first 85 patients (out of a scheduled total of 150 patients) enrolled in the TRITON 2 trial of the PARP inhibitor rucaparib (Rubraca) … READ MORE …

Understanding the genetics of prostate cancer diagnosis and treatment

For those who are interested in this evolving topic, we recommend listening to Dr. Charles Ryan’s 16-minute-long discussion with Heather Cheng, MD, PhD, entitled “Genetic evaluation and counseling in prostate cancer treatment”. … READ MORE …

Two Phase III trials of PARP inhibitors in mCRPC

There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Second PARP inhibitor approved by FDA (but still not for prostate cancer)

A second PARP inhibitor has recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with BRCA1/2 mutations and advanced ovarian cancer who have already received two types of chemotherapy. … READ MORE …